Although clinical trials of STING-agonist nanoparticles are still lacking, their use in preclinical settings allows for better tumor penetration, reduced systemic toxicity, and potentially increased efficacy of PD-1/PD-L1 combination therapy. This evidence concerns the gene STING1 and neoplasm.